skip to Main Content

Our Mission

Our mission is to pioneer the next wave of modern medicines to treat and cure the most significant diseases facing mankind today.

Although mankind has made dramatic advances in fighting disease to date, some of the deadliest afflictions remain uncured, including cancer and autoimmune disorders. Since its inception, the biotechnology industry has played a major role in developing new therapies. Even though the first wave of therapies has been effective, a new era of modern medicine is now emerging. Recent discoveries have provided insights into how we can better utilize the immune system to fight disease the way nature intended, and new advances in bioengineering have provided ways to leverage the immune system to our advantage. We believe understanding the complex interactions between molecules and cells will provide the key to the next generation of breakthrough therapies. The world of treatment possibilities abounds with this knowledge and we are positioned to translate these findings into new medicines to better the human condition.

Pipeline

Our fully owned and partnered programs are differentiated by a consistent focus on first-in-class or best-in-class targets across multiple indications where our product candidates have strong potential.

News

FEB 28, 2019
Abpro and NJCTTQ Enter Into Partnership For Development of Multiple Novel Bispecific Antibodies
Read More →
NOV 29, 2016
Medimmune and Abpro Enter into A Collaborative Agreement For a Novel Bispecific Antibody
Read More →
MAY 20, 2016
Abpro Announces Agreements with Two Boston Hospitals
Read More →
APR 25, 2016
Abpro Announces Investment and Partnership with Essex Bio
Read More →

Careers

Abpro offers competitive salaries and generous benefits with the opportunity to learn and grow in an employee-driven culture. We are seeking individuals with infectious enthusiasm, passion, and conviction who will be committed to our core values and mission. If you thrive in an upbeat, energetic, collaborative environment where every individual counts, we’re looking for you!

Back To Top